Name | Number of supported studies | Average coverage | |
---|---|---|---|
lung | 14 studies | 38% ± 18% | |
kidney | 8 studies | 28% ± 13% | |
intestine | 8 studies | 32% ± 17% | |
eye | 8 studies | 25% ± 14% | |
brain | 8 studies | 23% ± 8% | |
pancreas | 4 studies | 53% ± 20% | |
peripheral blood | 4 studies | 23% ± 6% | |
uterus | 4 studies | 35% ± 20% | |
liver | 4 studies | 38% ± 21% | |
breast | 4 studies | 26% ± 6% | |
placenta | 3 studies | 49% ± 19% | |
bone marrow | 3 studies | 23% ± 7% | |
prostate | 3 studies | 23% ± 8% | |
skin | 3 studies | 22% ± 3% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 4229.02 | 1445 / 1445 | 100% | 166.64 | 183 / 183 |
ovary | 100% | 2829.09 | 180 / 180 | 100% | 238.91 | 430 / 430 |
pancreas | 100% | 2210.35 | 328 / 328 | 100% | 209.09 | 178 / 178 |
skin | 100% | 5086.42 | 1808 / 1809 | 100% | 277.23 | 472 / 472 |
uterus | 100% | 3553.42 | 170 / 170 | 100% | 297.78 | 458 / 459 |
brain | 100% | 3878.93 | 2639 / 2642 | 100% | 244.68 | 704 / 705 |
stomach | 100% | 3343.65 | 359 / 359 | 100% | 195.49 | 285 / 286 |
breast | 100% | 3769.97 | 459 / 459 | 100% | 261.01 | 1114 / 1118 |
intestine | 100% | 3675.70 | 966 / 966 | 100% | 240.54 | 525 / 527 |
liver | 100% | 2927.99 | 225 / 226 | 100% | 197.33 | 406 / 406 |
thymus | 100% | 3582.36 | 652 / 653 | 100% | 198.97 | 603 / 605 |
kidney | 100% | 4131.11 | 89 / 89 | 99% | 158.41 | 896 / 901 |
prostate | 100% | 3479.55 | 245 / 245 | 99% | 272.92 | 499 / 502 |
lung | 100% | 3598.24 | 576 / 578 | 100% | 258.67 | 1152 / 1155 |
bladder | 100% | 3806.33 | 21 / 21 | 99% | 271.65 | 499 / 504 |
adrenal gland | 100% | 5667.02 | 258 / 258 | 98% | 234.90 | 226 / 230 |
adipose | 100% | 3976.02 | 1204 / 1204 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 100% | 259.63 | 80 / 80 |
lymph node | 0% | 0 | 0 / 0 | 100% | 211.67 | 29 / 29 |
muscle | 100% | 9889.93 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 2630.80 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 264.34 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 225.74 | 1 / 1 |
blood vessel | 100% | 3815.90 | 1333 / 1335 | 0% | 0 | 0 / 0 |
heart | 98% | 4043.50 | 844 / 861 | 0% | 0 | 0 / 0 |
peripheral blood | 62% | 1403.86 | 578 / 929 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006979 | Biological process | response to oxidative stress |
GO_0006508 | Biological process | proteolysis |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0000502 | Cellular component | proteasome complex |
GO_0005813 | Cellular component | centrosome |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005839 | Cellular component | proteasome core complex |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0019774 | Cellular component | proteasome core complex, beta-subunit complex |
GO_0005737 | Cellular component | cytoplasm |
GO_0005634 | Cellular component | nucleus |
GO_0008233 | Molecular function | peptidase activity |
GO_0004175 | Molecular function | endopeptidase activity |
GO_0005515 | Molecular function | protein binding |
GO_0004298 | Molecular function | threonine-type endopeptidase activity |
Gene name | PSMB5 |
Protein name | Proteasome subunit beta type-5 (EC 3.4.25.1) (Macropain epsilon chain) (Multicatalytic endopeptidase complex epsilon chain) (Proteasome chain 6) (Proteasome epsilon chain) (Proteasome subunit MB1) (Proteasome subunit X) Proteasome 20S subunit beta 5 |
Synonyms | MB1 X LMPX |
Description | FUNCTION: Component of the 20S core proteasome complex involved in the proteolytic degradation of most intracellular proteins. This complex plays numerous essential roles within the cell by associating with different regulatory particles. Associated with two 19S regulatory particles, forms the 26S proteasome and thus participates in the ATP-dependent degradation of ubiquitinated proteins. The 26S proteasome plays a key role in the maintenance of protein homeostasis by removing misfolded or damaged proteins that could impair cellular functions, and by removing proteins whose functions are no longer required. Associated with the PA200 or PA28, the 20S proteasome mediates ubiquitin-independent protein degradation. This type of proteolysis is required in several pathways including spermatogenesis (20S-PA200 complex) or generation of a subset of MHC class I-presented antigenic peptides (20S-PA28 complex). Within the 20S core complex, PSMB5 displays a chymotrypsin-like activity. . |
Accessions | ENST00000493471.2 [P28074-2] ENST00000555895.5 G3V3K3 ENST00000460922.2 ENST00000425762.2 [P28074-3] ENST00000334454.10 G8JLC2 H0YJM8 P28074 ENST00000361611.11 [P28074-1] |